@misc{oai:repo.qst.go.jp:00065640,
 author = {Shimada, Hitoshi and Shinotoh, Hitoshi and Sahara, Naruhiko and Hirano, Shigeki and Furukawa, Shogo and Takahata, Keisuke and Kimura, Yasuyuki and Yamada, Makiko and Yoshiyama, Yasumasa and Zhang, Ming-Rong and Ito, Hiroshi and Higuchi, Makoto and Kuwabara, Satoshi and Suhara, Tetsuya and 島田 斉 and 篠遠 仁 and 佐原 成彦 and 平野 成樹 and 古川 彰吾 and 高畑 圭輔 and 木村 泰之 and 山田 真希子 and 吉山 容正 and 張 明栄 and 伊藤 浩 and 樋口 真人 and 須原 哲也},
 month = {Jan},
 note = {Background and aims: Fibrillary tau pathology is considered to be a promising target for imaging and therapy in Alzheimer’s disease (AD) and non-AD tauopathies such as progressive supuranuclear palsy (PSP), corticobasal syndrome (CBS) and frontotemporal dementia (FTD). [11C]PBB3 is a novel tau imaging PET ligand, which could visualize the tau deposition in AD and non-AD tauopathies. The aim of this study is to investigate the diagnostic utility and the clinical significance of tau PET imaging with [11C]PBB3.
Methods: Participants were 16 mild cognitive impairments (MCI) patients, 21 AD patients, ten PSP patients, nine CBS patients, four FTD patients, and 34 healthy controls (HCs). We performed PET scans with [11C]PBB3, [11C]PIB and [18F]FDG PET and MRI scans. Standardized uptake value ratio was calculated for PET images using the cerebellar cortex as reference region. In a subset of patients, lumber puncture was also performed to measure levels of cerebrospinal fluid (CSF) tau proteins. We assessed diagnostic utilities of each PET by area under the curve (AUC) of the receiver-operating characteristic.
Results: Ten of 16 MCI patients, 20 of 21 AD patients, one of nine CBS patient, one FTD patient, and three of 34 HCs were PIB-positive. Regional distribution of [11C] PBB3 retention relative to HCs was different among patient groups, and was associated with neurological symptoms characteristic of each disease. [11C]PBB3-PET discriminated between MCI and AD (AUC = 0•990; 95% CI, 0•964-1•000) and between HC and MCI (0•981; 0•941-1•000). [11C]PBB3 binding correlated well with cognitive dysfunctions, but not with CSF tau.
Conclusions: [11C]PBB3-PET enables differentiation of patients with MCI from those with AD and HCs, and provide objective indices reflecting the disease severity. Furthermore, [11C]PBB3 PET is helpful to visualize specific distribution patterns of tau pathology associated with each neurological manifestation in a variety of non-AD tauopathies., Human Amyloid Imaging 2015},
 title = {Diagnostic Utility and Clinical Significance of Tau PET imaging with [11C]PBB3 in Diverse Tauopathies},
 year = {2015}
}